Piramal approves $20m capacity expansion for hormonal, ADC manufacturing
Contract manufacturer Piramal recently approved a $20m capacity expansion for hormonal and antibody drug conjugate (ADC) manufacturing at its facilities in Morpeth, UK, and Grangemouth, Scotland.
The expansions come as the company also recently invested $40m in new equipment and technologies and related infrastructure. The company said the investments were part of a broader plan to better serve its customers.
On the ADC side, Piramal has invested steadily from a 2011 capacity expansion to a $2.5m expansion in 2013.
In addition, the company recently completed a $10m green field facility to double its discovery services capacity.